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Abstract: The successful delivery of optimal peri-operative care to pediatric heart transplant recipients is a vital determi-
nant of their overall outcomes. The practitioner caring for these patients must be familiar with and treat multiple simulta-
neous issues in a patient who may have been critically ill preoperatively. In addition to the complexities involved in treat-
ing any child following cardiac surgery, caretakers of newly transplanted patients encounter multiple transplant-specific 
issues. This chapter details peri-operative management strategies, frequently encountered early morbidities, initiation of 
immunosuppression including induction, and short-term outcomes.  
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INTENSIVE CARE MANAGEMENT 
Hemodynamic Instability 
  Adequate monitoring of the post-operative heart trans-
plant patient is essential. Recently published International 
Society for Heart and Lung Transplantation (ISHLT) guide-
lines for the peri-operative monitoring of both adult and pe-
diatric heart transplant recipients are detailed in Table 1 [1]. 
Of these, standard pediatric monitoring would include all 
except assessment of pulmonary arterial wedge pressure 
(PAWP) and cardiac output via Swan-Ganz catheters due to 
concerns of catheter size and maintaining appropriate cathe-
ter position especially in smaller recipients. However, con-
tinuous, direct measurement of pulmonary artery pressures is 
often monitored in pediatric patients, particularly those with 
elevated pre-transplant pulmonary arterial pressures. 
  Peri-operative hemodynamic instability can be present 
and is secondary to multiple causes including graft reperfu-
sion injury, post-bypass inflammatory response, elevated 
pulmonary vascular resistance, and labile fluid status. 
Vasoactive pharmacologic support is routinely necessary to 
augment marginal cardiac output mediated by ventricular 
dysfunction and associated systemic hypotension. The 
catecholamine stores of the newly transplanted heart are of-
ten depleted necessitating exogenous catechol supplementa-
tion [2]. Continuous infusions of isoproterenol, dobutamine, 
dopamine, and low-dose epinephrine all increase left ven-
tricular contractility. These agents can be similarly used to 
improve right ventricular function. Alpha-adrenergic ago-
nists including high-dose epinephrine (>0.05mcg/kg/min), 
phenylephrine, and norepinephrine may be used to achieve 
adequate systemic perfusion pressure when necessary. With 
limited supporting adult data, because of its specific periph-
eral vasoconstricting properties, vasopressin has been rec-
ommended as treatment for vasodilatory shock and may be 
considered when -agonists have been ineffective in combat-
ing refractory low systemic vascular resistance [1]. If sig-
nificant hemodynamic instability is present and unresponsive  
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Table  1. ISHLT Guidelines for Post-Heart Transplant Moni-
toring [1] 
Post-operative 12-lead ECG  Invasive arterial pressure moni-
toring 
Right atrial or central venous pres-
sure  monitoring 
Left atrial of pulmonary artery 
wedge  pressure monitoring 
Intermittent measures of cardiac 
output 
Arterial oxygen saturation 
monitoring 
Intra-operative transesophageal  
echocardiogram  
Continuous assessment of urinary
  
output 
 
to standard pharmacologic interventions, direct surgical ex-
ploration to assess for and treat potential cardiac tamponade 
should be strongly considered. Hyperacute (pre-formed anti-
body mediated) rejection may also be an etiology for cases 
of profound hemodynamic instability [1] and often requires 
aggressive therapies including mechanical circulatory sup-
port and plasmapheresis for reversal. 
  As mentioned above, when pharmacologic treatment 
alone is inadequate to support the failing graft, mechanical 
circulatory support may be required. The ISHLT recommen-
dations state that extra-corporeal membrane oxygenation 
(ECMO) is the first choice for support in the setting of pri-
mary graft failure, and ECMO should be instituted immedi-
ately in pediatric patients with progressive post-operative 
allograft dysfunction [1]. Several previous reports have 
shown that this modality has been used successfully to sal-
vage severe graft failure following pediatric transplantation 
[3] [4]. Tissot and colleagues reported that 9% of their trans-
plant recipients required peri-operative ECMO for right ven-
tricular or biventricular failure, and/or hyperacute rejection. 
Of those, 54% survived to hospital discharge, and, impor-
tantly, the long-term survival of this group was not signifi-
cantly different from a non-ECMO comparison cohort. 
These investigators also found that, while pre-transplant car-
diac diagnosis was not a risk factor, longer total ischemic 
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ciated with an increased risk for peri-operative ECMO sup-
port [3].  
Bleeding and Volume Status 
  Post-operative bleeding can be significant in children 
following heart transplantation. Causes are multi-factorial 
and include previous congenital cardiac surgery necessitating 
extensive dissection, cardiopulmonary bypass, multiple su-
ture lines, pre-transplant heparinization for VAD or ECMO 
support, and poor pre-operative nutritional status. Platelet 
and fresh frozen plasma infusion should be used as necessary 
to control hemorrhage. Recombinant factor VII may be use-
ful for refractory bleeding [1]. Volume resuscitation includ-
ing packed (preferably leukocyte reduced if not CMV nega-
tive) red blood cells may be necessary, but should be admin-
istered with caution given the increased risk for allosensitiza-
tion from transfused leukocytes which may express non-
donor matched HLA antigens. Patients with refractory hem-
orrhage or those demonstrating clinical evidence of cardiac 
tamponade should be surgically explored.  
  Fluid management may be challenging. Care must be 
exercised to provide adequate cardiac filling without causing 
substantial overload to the already stressed right ventricle. 
Goal central venous pressures of 5-12mmHg should be tar-
geted [1]. Fluid resuscitation with colloid should be per-
formed when necessary to maintain adequate filling. Fluid 
overload can also occur following volume resuscitation for 
hypotension and associated capillary leak after surgery and is 
typically managed with intermittent or continuously infused 
loop diuretics and adjunctive use of thiazides when needed. 
Acute renal failure occurs post-operatively in 3-10% of 
transplant recipients [5]. Hemodialysis may be necessary for 
refractory fluid overload and oliguria in the presence of a 
rising serum creatinine. Multi-disciplinary team management 
including nephrology is often useful in this circumstance.  
Hypertension 
  Patients often develop systemic hypertension in the im-
mediate post-operative period. This can be secondary to 
baroreflex-mediated hypertension, catecholamine dysregula-
tion from low cardiac output pre-transplant, significant pre-
existing renal injury, and newly initiated immunosuppressive 
medications such as corticosteroids or calcineurin inhibitors 
[6]. Heart-transplant recipients can also develop salt-
sensitivity related to blunted diuretic and natriuretic re-
sponses caused by a failure to suppress fluid regulatory hor-
mones. This may be due to altered cardiorenal-neuroendoc-
rine interactions in the context of a denervated graft [7]. Sys-
temic hypertension should be treated to minimize afterload 
on the graft left ventricle (LV). Calcium-channel blockers, 
angiotensin converting enzyme inhibitors or a combination 
of both usually provide adequate blood pressure control. 
Donor Size Mismatching 
  Recipient/donor size mismatching can also influence 
post-operative course. “Big heart syndrome” results when 
the donor size is significantly larger than the recipient. In the 
early transplant period, donor/recipient weight ratio mis-
matches of >2.0 may result in systemic hypertension syn-
drome with associated central nervous system symptoms 
including seizures and coma. Treatment consists of anti-
hypertensive medication titration to achieve a normal blood 
pressure for age [8]. An inappropriately small donor heart 
size has been associated with increased mortality, and a do-
nor/recipient weight ratio <1 has been reported as a signifi-
cant predictor of fatal post-operative heart failure [9]. 
  Post-operative pericardial effusions develop in 9-21% of 
adult recipients [10, 11]. The incidence in pediatric patients 
is unknown but likely similar to adults and may, in part, be 
related to an increased pericardial volume created after a 
dilated heart is replaced with normal-sized heart that fills 
with fluid. Unless the effusion is hemodynamically compro-
mising or there is a strong suspicion of an infectious etiol-
ogy, the effusion does not require surgical or percutaneous 
drainage and can be monitored serially by echocardiography 
[1]. Hemodynamic instability in the presence of an effusion 
warrants surgical or catheter-based drainage.  
Arrhythmias 
  Post-transplant sinus node dysfunction is common with a 
reported prevalence as high as 44% [12] and is likely related 
to myocardial ischemia and surgical manipulation [13] [14]. 
Due to diastolic dysfunction and impaired filling of the 
transplanted heart, atrio-ventricular (AV) synchrony and 
adequate heart rate are often required to maintain cardiac 
output. A continuous isoproterenol infusion is often used as a 
chronotrope to increase heart rate. Alternatively, either AV 
pacing or, with intact AV node conduction, atrial pacing 
alone may be performed via temporary pacing wires placed 
at the time of surgery. The ISHLT guidelines recommend 
pharmacologic treatment or pacing to maintain a minimum 
heart rate of 90 beats/min [1]. This rate can be increased for 
effect, and higher rates should be targeted for smaller pa-
tients. Although sinus node dysfunction is typically transient 
[12], some patients will have permanent sinus node dysfunc-
tion and require permanent pacing. A 2-5% prevalence of 
pacemaker placement has been reported with sick sinus syn-
drome and complete heart block constituting the most com-
mon indications [14] [15].  
PULMONARY VASCULAR RESISTANCE 
  As discussed in another chapter, elevated pulmonary vas-
cular resistance (PVR) is a significant risk factor for early 
post-transplant right heart failure and mortality in both pedi-
atric and adult patients and is often multi-factorial in origin 
[16] [17] [18] [19]. Several studies have demonstrated an RV 
failure risk up to 75% with a 15% mortality risk among pa-
tients with pre-transplant PVRi (indexed to body surface 
area) >6 Wood units x m
2. This contrasts with a 20% risk of 
RV failure in patients without increased PVR [20] [21] [17]. 
The mechanism of RV failure in the immediate post-OHT 
period is multifactorial. The donor heart, already exposed to 
donor-related myocardial strain, ischemia, cardioplegia, and 
surgical trauma, is then exposed to elevated recipient PVR 
often complicated by bypass-induced transitional pulmonary 
vascular hyper-reactivity [22]. This sudden and dramatic 
increase in PVR can cause rapid, and possibly irreversible, 
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  Given this risk, particular attention must be paid to ade-
quate control of the post-operative PA pressures. An in-
dwelling pulmonary arterial line will permit continuous post-
operative pulmonary arterial pressure monitoring and facili-
tate treatment when elevated in an effort to avoid strain-
related RV myocardial failure. Conventional treatment op-
tions in this setting have included increased sedation with 
neuromuscular blockade if necessary, avoidance of hyper-
capnia and hypoxia, and serum alkalinzation (pH 7.45-7.55).  
  Over the last decade, treatment with pulmonary vasoac-
tive substances has been used as first-line therapy or in con-
junction with the above-listed maneuvers. Nitric oxide (iNO) 
is an inhaled pulmonary vasodilator that rapidly and effec-
tively reduces PVR and RV pressure in the post-transplant 
patient [23] [24]. Nitric oxide may be started intra-opera-
tively when significant RV dysfunction or failure is first rec-
ognized, and some centers empirically treat all patients with 
pulmonary vasodilators prior to weaning from cardiopul-
monary bypass as recent studies have shown this strategy 
decreases the incidence of post-operative right heart failure 
[25]. Often, iNO is continued for several days post-
operatively when RV failure is a concern [17]. Despite its 
efficacy, iNO is not a long term treatment option due to its 
toxicities (i.e. methemoglobinemia), need for continuous 
delivery, and considerable cost which have motivated inves-
tigators for explore alternative agents to treat post-operative 
pulmonary hypertension.  
  Iloprost is an aerosolized prostacyclin derivative and po-
tent pulmonary vasodilator. When inhaled, it preferentially 
dilates local vascular beds in well ventilated areas of the lung 
and has been effective in treating primary pulmonary hyper-
tension in adults [26]. While experiential data is limited, 
iloprost has been effective in decreasing pulmonary vascular 
resistance in a small series of adult post-transplant recipients 
[27, 28], and comfort with its use in pediatrics is growing.  
  Sildenafil, a phosphodiesterase type-5 inhibitor in pul-
monary vascular smooth muscle, has therapeutic effects 
within hours of dosing and has been effective in reducing 
pulmonary artery pressures [20, 29]. Daftari and colleagues 
(2010) reported their success with initiating sildenafil in 
combination with other pulmonary vasodilators in the imme-
diate post-transplant period for 7 patients with pre-operative 
PVR >6 Wood units. Prior to transplant, all patients had been 
treated with sildenafil, bosentan, or both. Post-operative sild-
enafil therapy, and in some cases additional pulmonary 
vasodilator therapy, was continued until PVR normalized. 
All 7 patients were reportedly alive at 1 year post-transplant.  
PRIMARY GRAFT FAILURE 
  Primary graft failure is defined as early post-transplant 
cardiac failure without an identifiable immunologic or anat-
omic etiology [19, 22, 30] and has been reported in 20%-
30% of patients within the first 30 days post-transplant [19] 
[31]. The ISHLT reported >20% of deaths within 30 days of 
transplant were due to primary graft failure, making it the 
leading cause of peri-operative mortality [32]. In infants, 
more than 50% of deaths in the first post-transplant month 
have been attributed to primary graft failure [33]. Recipient 
congenital heart disease, pre-transplant mechanical support, 
increasing donor ischemic time, anoxia-mediated donor 
death, prolonged donor resuscitation time, and increasing 
donor:recipient weight ratio have all been associated with 
increased graft failure risk [19], while donor blood type O+ 
and donor hyperdynamic systolic function are protective 
[19]. When present, treatment is symptomatic and directed at 
increasing contractility as well as minimizing afterload and 
pulmonary vascular resistance. ECMO should be promptly 
instituted when standard post-operative pharmacologic 
treatment is inadequate. Given the risk of graft loss and mor-
tality coupled with the known risk factors for primary graft 
failure, the importance of rigorous patient and donor selec-
tion criteria cannot be overstated. 
ABO INCOMPATIBLE TRANSPLANTATION 
  ABO incompatible (ABOi) transplantation has been de-
tailed in a separate section. However, some specific issues 
are particularly relevant in the immediate post-operative care 
of ABOi recipients and are, therefore, worthy of reiteration. 
Special transfusion protocols must be used peri-transplant to 
avoid early and late donor blood group sensitization [Table 
2] [34]. Although the risk of isohemagluttinin antibody me-
diated rejection is low by published reports [35], isohema-
gluttinin mediated rejection must be considered a potential 
cause of any acute graft failure. In Dipchand and colleagues’ 
review of their extensive experience with ABOi transplanta-
tion, donor specific isohemagluttinin antibodies developed in 
2/35 patients, neither experienced significant graft dysfunc-
tion, and, with therapy, these antibodies disappeared within 8 
weeks and did not recur [35]. Roche and colleagues (2008) 
similarly found low rates of cellular rejection in their ABOi 
patient cohort (n=21) [36]. For surveillance and assurance of 
adequate treatment in patients who do develop donor specific 
isohemagluttinin antibodies, serum titers must be collected 
routinely in the immediate post-transplant period. 
  Standard immunosuppression regimens are used in ABOi 
transplants with no increased risk of rejection compared to 
ABOc patients [35, 36].  
INFECTION 
  Infections occur in up to 25% of pediatric recipients dur-
ing the early post-operative period, and 60% of these infec-
tions are bacterial [37]. The most common bacterial patho-
gens reported are Staphylococcus, Pseudomonas, and En-
terobacter cloacae [38]. Blood stream and pulmonary infec-
tions are most common followed by urinary tract and surgi-
cal site infections [39, 40]. The ISHLT guidelines recom-
mend peri-operative antibiotic prophylaxis against skin flora, 
particularly Staphylococcus aureus, and, if donor infection is 
confirmed, additional targeted therapy against the potentially 
transmittable donor organism should be strongly considered 
[1]. 
  Up to 7% of children may develop a peri-operative fun-
gal infection following transplant [39]. This infection type is 
often localized, but disseminated disease can occur and is 
associated with an increased risk of death during the first 
year post-transplant [41]. The most common pathogens are 
Candida species and molds, specifically Aspergillus [37]. 
Initiation of antifungal prophylaxis with nystatin or clotri-
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  Pneumocystis jiroveci infection has been reported in ap-
proximately 4% of adult heart transplant recipients and pre-
sents with acute and potentially fatal systemic illness [42]. 
There have been fewer confirmed infections in pediatric pa-
tients, but because of its virulence in immunosuppressed 
patients, current recommendations are for 3-24 months of 
post-transplant prophylaxis with trimethoprim/sulfamethoxa-
zole, or aerosolized pentamidine isethionate, pyrimethamine 
or dapsone (with or without trimethoprim) in patients with 
sulfa allergies [1]. 
  Cytomegalovirus (CMV) infection is the most common 
infectious agent identified after pediatric transplant, and the 
incidence in post-transplant patients who have not received 
CMV prophylaxis is 60-90% [37, 43]. In contrast to adults in 
which previous CMV exposure is common, fewer pediatric 
donors and recipients are CMV seropositive (CMV+) in-
creasing the risk of CMV infection in pediatric recipients 
[44]. Often this infection consists of benign viremia and does 
not lead to clinically relevant disease [44]. However, up to 
18% of pediatric CMV-mismatched patients (R-/D+) de-
velop clinical CMV disease with typical findings of fever, 
appearance of atypical lymphocytes, lymphopenia, myalgias, 
arthralgias, thrombocytopenia, and renal impairment; severe 
manifestations of disease may include interstitial pneumonia, 
esophagitis, gastritis, colitis, retinitis, and encephalitis [44]. 
CMV+ recipients can also develop CMV disease, either from 
reactivation or new donor transmitted disease [43].  
  Because CMV disease can occur early after transplant 
and the peri-operative morbidity can be significant, prophy-
lactic and pre-emptive strategies to minimize or prevent 
CMV infection/disease have been developed. Prophylaxis 
consists of intravenous (IV) ganciclovir or oral valganci-
clovir initiated in the early post-operative period with a goal 
of preventing CMV infection [45]. Pre-emptive therapy con-
sists of close monitoring of recipient CMV status, either by 
quantitative DNA-PCR or CMV antigenemia, and initiating 
treatment when a previously CMV negative patient becomes 
CMV positive thereby minimizing transition of infection into 
significant CMV disease [45]. When both strategies were 
compared in a recent adult cohort study, prophylaxis was 
superior to pre-emptive therapy with a reduction in CMV 
infections, decrease in subsequent CMV disease, and reduc-
tion in coronary intimal thickening by intravascular ultra-
sound [46]. Prophylaxis with IV ganciclovir, oral valganci-
clovir, or CMV immunoglobulin (CytoGam) is commonly 
used by pediatric transplant centers for CMV-mismatched 
patients and has a survival benefit over non-prophylaxis 
[47]. Though not standard practice, post-operative dual-
therapy with CytoGam and ganciclovir is effective both as 
preemptive and prophylactic therapy and has been shown to 
attenuate symptoms in active disease [43, 48, 49]. The recent 
ISHLT guidelines recommend initiating treatment with oral 
or IV ganciclovir or valganciclovir for CMV+ or CMV-
mismatched pediatric recipients [1].  
REJECTION 
  Despite evolving immune therapies, rejection continues 
to be a major source of morbidity and mortality in the imme-
Table 2.  Transfusion Guidelines for the ABO-Incompatible Patient [34] 
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diate post-operative period. Rejection is an adaptive immune 
response and, for discussion purposes, is usually divided into 
2 forms: T-cell mediated and antibody (humoral) mediated.  
  Acute cellular rejection is T-cell mediated and usually 
occurs after the first post-operative week. Many transplants 
recipients will experience some degree of ongoing non-
damaging cellular rejection. This asymptomatic, mild rejec-
tion (ISHLT 1R) does not typically require treatment as 
there is frequent spontaneous resolution, and treatment of 
these episodes has not been associated with survival benefit 
[50, 51]. However, more significant treatable rejection also 
occurs, and nearly 40% of adult recipients have reportedly 
experienced as least one episode of grade 2R rejection in 
the first post-transplant year [32], with the highest incidences 
during the initial 3 months [52]. In recent years, however, 
incident treatable rejection has decreased, possibly due to 
novel immunosuppressive regimens or combinations; how-
ever, the incidence of rejection causing hemodynamic com-
promise and death has remained unchanged [53]. Rejection 
remains the primary cause in 10% of all mortalities within 
the first 30 days following transplant [32]. 
  Biopsy-proven rejection grade 2R, with or without 
clinical symptoms, is medically treated by most transplant 
physicians. Pulsed intravenous corticosteroids are the usual 
initial treatment in the immediate post-operative period [51]. 
Lack of response to steroid treatment and/or progressive 
clinical deterioration can be treated with more aggressive 
cytolytic therapy, usually anti-thymocyte globulin [54]. 
  Cellular rejection surveillance is determined by the pa-
tient’s overall risk for rejection and continues to be center 
dependent. Endomyocardial biopsy (EMB) is the gold stan-
dard for diagnosis [55]. Initial EMB is performed in older 
pediatric patients within the first 2 weeks after transplant 
[55, 56]. Infants, possibly due to the immaturity of their im-
mune system, appear to be at decreased risk for rejection 
[57]. Many centers perform routine EMB on infants signifi-
cantly less frequently or not at all, instead depending on 
physical exam and echocardiogram to aid in diagnosis, and 
biopsy only for clinical indications [58, 59]. With any clini-
cal deterioration in the early post-operative period, evalua-
tion of and treatment for rejection as the potential cause 
should be considered. 
  Humoral rejection results from an antibody-mediated 
response to mismatched human leukocyte antigens (HLAs) 
present within the donor myocardium and vascular endothe-
lium, and the number of mismatches may influence the speed 
and degree of rejection [60]. Pathologically, this form is 
characterized by a lack of significant cellular rejection on 
EMB and is often accompanied by left ventricular dysfunc-
tion and detection of donor-specific antibody in the recipient 
serum [60] as discussed in another chapter. Initial treatment 
is similar to cellular-rejection and includes pulsed corticos-
teroids and cytolytic therapy (often anti-thymocyte globulin); 
however, adjunctive therapy to target B-cell activity and 
decrease circulating antibodies is also frequently used. Plas-
mapheresis and intravenous immune globulin G (IVIg) ther-
apy have been employed to remove pre-formed antibody and 
are frequently used by pediatric transplant physicians [61-
63]. Cyclophosphamide and mycophenolate mofetil have 
also been used to directly suppress B-cell populations and 
Rituximab, a monoclonal antibody directed against the B-
cell CD20 receptor, has been successfully used to treat hu-
moral rejection [64-66].  
ALLOSENSITIZATION 
  Genetically programmed human leukocyte antigens 
(HLA) are divided into 2 distinct classes (I and II) and ex-
pressed on all somatic cells giving each of us a distinct HLA 
signature. Immune recognition of “non-self” HLA antigens 
results in production of anti-HLA antibodies and is termed 
allosensitization. The most detailed assessment of anti-HLA 
antibody is currently performed via a panel reactive antibody 
(PRA) test using Luminex single-antigen bead technology. 
Allosensitization in children with congenital heart disease is 
particularly prevalent as these children are often exposed to 
many potential sensitizing events prior to transplant. In this 
group, production of anti-HLA antibody may occur during 
use of a ventricular assist device, prior blood transfusions 
(especially platelets), or following implantation of cryopre-
served homografts which are used in many surgical recon-
structions [67-69]. Interestingly, sensitization among infants 
and young children supported with extra-corporeal mem-
brane oxygenation (ECMO) may occur less frequently than 
in children with ventricular assist devices [70]. Patients with 
PRAs >10% have an increased risk of rejection and lower 
graft survival rates [62, 71, 72]. Previously, these patients 
required prospective crossmatching, which necessitated 
transport of receipient serum to the donor center for reaction 
with donor serum prior to harvest, to identify a suitable or-
gan. Because this process not only delayed donor allocation 
but also reduced the recipient’s potential donor pool due to 
distance restrictions, most centers now attempt pre-transplant 
desensitization. Although there is currently no universally 
accepted desensitization protocol, multiple agents have been 
used including oral methotrexate, cyclophosphamide and 
mycophenolate mofetil. Successful desensitization after use 
of these drugs was generally poor, and more recently, clini-
cians have implemented strategies using Rituximab and 
IVIg. IVIg is first administered to bind and remove circulat-
ing anti-HLA antibodies. Rituximab is then serially adminis-
tered to suppress CD20+ B-cells and limit the future produc-
tion of anti-HLA producing plasma cells, leading to a slow 
decrease in anti-HLA antibodies over time [73]. Small trials 
are ongoing to assess the effectiveness of this approach. An-
ecdotal reports of Bortezomib have suggested this agent may 
have additional efficacy over Rituximab, but randomized 
trials have not yet confirmed its utility. Bortezomib is a pro-
teosome inhibitor that has been shown in pre-clinical studies 
to promote the emergence of regulatory T-cell populations 
that inhibit stimulated effector T-cells, thereby limiting the 
pathway ultimately producing anti-HLA antibodies [74]. 
There is very limited data on Bortezomib in heart transplan-
tation, but small studies in renal transplant patients suggest it 
may have a role in desensitization [74]. Regardless of agent 
used, in most cases, desensitization will not be completely 
effective and will require virtual-crossmatching to maximize 
the success of transplanting a highly-sensitized patient. This 
technique enables the recipient center to remotely predict the 
risk of accepting a given donor since Luminex technology 
allows quantitative identification of potential donor-specific 
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propriately HLA-matched organs and minimize the risk of 
peri-operative antibody-mediated rejection. While longer-
term data is not yet available, graft survival after virtual 
crossmatching is acceptable with low humoral rejection rates 
[70, 75].  
INDUCTION THERAPY 
  Induction therapy refers to the administration of a special 
group of immunosuppressant agents in the pre- and peri-
operative period to rapidly disable the normal host response 
toward the transplanted graft [32]. Although there has been a 
recent trend toward increased usage, induction therapy is not 
considered a universal standard of care and only 50-70% of 
centers currently report its use (Fig. 1) [76].  
  After their initial intent to induce “immune tolerance” 
failed, practical application of these drugs evolved into 
strategies to reduce early rejection, which was associated 
with improved peri-operative survival [77-81]. More re-
cently, induction therapy has been used to delay the initiation 
of nephrotoxic calcineuin inhibitors and to achieve steroid 
avoidance [81-83]. Despite its success in achieving these 
goals, the universal use of induction therapy was nonetheless 
limited due to mixed reports that it may have increased the 
risk for infection and post-transplant lymphoproliferative 
disease (PTLD). Several adult studies found increased inci-
dence of CMV and fungal infections [84, 85] or PTLD [86] 
while others found no association with these events [87, 88]. 
Likewise, pediatric patients are not universally induced due 
to similarly conflicting results [79, 89-91]. However, in a 
recent study of patients enrolled in the Pediatric Heart 
Transplant Study database, Gajarski and colleagues analyzed 
2374 transplanted patients, 53% of whom received induction 
therapy. Despite use of variable induction agents (detailed 
below), the authors found that when compared to non-
induced patients, the induction group had a significantly 
lower rate of PTLD and a similar infection rate. The authors 
concluded that induction strategies can be implemented 
without increasing early infection or PTLD risk (Fig. 2, 3) 
[92].  
Monoclonal Antithymocyte Antibody 
  Muromonab (OKT3) is a murine antibody targeting the 
human T-cell CD3 receptor which disrupts its ability to re-
spond to an antigen challenge and leads to T-cell opsiniza-
tion and removal by circulating macrophages [93]. Side ef-
fects include fever, rash, aseptic meningitis, and anaphylaxis. 
In addition, the opsinization of CD-3+ T-cells can lead to the 
release of multiple cytokines causing headache, nausea, 
vomiting, fever, chest pain, and dyspnea from pulmonary 
edema, collectively termed “cytokine release syndrome” [22, 
93]. Compared with other agents, the recent mega-analysis 
found that OKT3 was the only induction agent associated 
with an increased risk for PTLD and infection with CMV or 
fungus [92]. Because of these side effects and unacceptable 
morbidities, OKT3 use has been largely abandoned in favor 
of alternative agents (listed below) with similar benefits but 
reduced adverse event profiles [94].  
Polyclonal Antithymocyte Globulin (ATG)  
  Two polyclonal antithymocyte antibody preparations are 
available (Table 3). Equine ATG (ATGAM, Pharmacia Up-
john, Pfizer, NY) is purified after horse immunization with 
human T-cells, and rabbit ATG (Thymoglobulin, Genzyme 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Induction immunosuppression for transplants performed January 2001–June 2009. ALG, anti-lymphocyte globulin; ATG, anti-
thymocyte globulin; IL-2R, interleukin-2 receptor [32]. 116    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Schumacher and Gajarski 
Corporation, Cambridge, MA) is produced by rabbit immu-
nization with human thymocytes. Both preparations lead to 
production of polyclonal antibodies against multiple human 
antigens including immune cell surface receptors and HLA 
antigens expressed on T-lymphocytes [94]. Injection of the 
polyclonal sera into humans leads to antibodies coating re-
cipient immune cells, which results in rapid depletion of re-
cipient T-lymphocytes via opsinization, phagocytic, and 
natural killer cell mechanisms [22, 94]. Individual transplant 
physicians dose these agents to target total lymphocyte 
counts of 0.1-0.3 (X10
3/mm
3) which appears efficacious 
without significantly increasing the risk of opportunistic in-
fections [79, 81, 94]. Direct comparisons of the horse- and 
rabbit-derived preparations showed that the rabbit prepara-
tion more potently decreased circulating lymphocyte counts 
without a change in safety profile [95]. No increased risk of 
infection or PTLD has been documented after ATG admini-
stration in several recent reports [79, 89, 92]. 
IL-2 Receptor Antagonists  
  Use of novel interleukin-2 receptor antagonists (IL-2Ra) 
has increased over the last several years (Table 3 ) [32]. 
These agents bind to the alpha-subunit of the IL-2 receptor 
on activated T-cells preventing T-cell proliferation and at-
tenuating the graft-directed immune response [93]. There are 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Curves represent freedom from PTLD stratified by receipt of induction. Note that induction therapy is associated with a higher free-
dom from lymphoma throughout the follow-up period. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Kaplan-Meier curve of freedom from infection stratified by use of induction. No difference was identified in probability of infection 
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two currently available forms utilized in pediatric transplan-
tation: basiliximab (Simulect, Novartis, New Jersey, USA), a 
chimeric mouse/human antibody, and daclizumab (Zenapax, 
Roche Pharmaceuticals, New Jersey, USA), a humanized 
(>90% human, <10% mouse) antibody [94]. Several recent 
studies have shown IL-2R antagonists to be effective in re-
ducing the incidence of acute rejection [53, 83, 96]. Al-
though data evaluating these morbidities remains limited, 
compared to other induction agents, IL-2R antagonists may 
also be associated with a lower infection and PTLD event 
profile [97]. Interestingly, unlike other induction agents, 
basiliximab appears to confer better prevention of acute re-
jection when given prior to graft implantation [96]. Previ-
ously, clinicians believed that immunosuppressants given 
pre-operatively would be diluted or filtered from the circula-
tion during bypass. However, because basiliximab rapidly 
binds to its target molecule, important loss of drug during 
bypass is unlikely and prevention of early T-cell activation 
may be the key to this drug’s efficacy [96]. Basiliximab and 
daclizumab have not been studied in head-to-head random-
ized cardiac studies, however, data from pediatric renal 
transplantation demonstrated equivalent efficacy and safety 
between the two agents [98].  
IMMUNE MAINTENANCE THERAPY 
  Unless delayed by use of induction, maintenance immu-
nosuppression is routinely initiated within the first several 
post-operative days. Most maintenance regimens are triple-
therapy based and include a calcineurin inhibitor, cell cycle 
inhibitor and corticosteroid. 
Calcineurin Inhibitors 
  Calcineurin inhibitors (CNI) are the crux of current main-
tenance therapy (Table 4). CNIs inhibit the phosphatase ac-
tion of calcineurin, a key enzyme in the production pathway 
of multiple cytokines including IL-2. This action inhibits the 
expansion of CD4+ and CD8+ cell lines and differentiation 
of CD4+ T-cell subsets [94]. Currently, 2 CNIs are fre-
quently used, cyclosporine A (CSA, Neoral; Novartis Phar-
maceuticals Corporation) and tacrolimus (TAC, FK506, Pro-
graf; Astellas Pharmaceuticals Inc). Until recently, CSA was 
the mainstay of maintenance therapy, however, the 2009 
ISHLT pediatric heart update reported that 58% of patients 
were started on TAC compared with 38% on CSA [32]. This 
shift in treatment regimen is likely multifactorial. While sev-
eral studies have demonstrated equivalent graft survival be-
tween the two drugs [99, 100], CSA has a less favorable 
cosmetic side effect profile and is associated with more lipid 
derangements. In addition, a recent meta-analysis found de-
creased risk of acute rejection with TAC compared to CSA 
[101], although other trials have failed to confirm this find-
ing [100, 102]. Even though there may be no difference in 
de-novo rejection rates when comparing the 2 agents, con-
version from CSA to TAC may be useful in controlling re-
current or treatment-refractory rejection [99, 100, 103]. 
Cell Cycle Inhibitors/Antiproliferatives 
  Azathioprine’s (AZA) active metabolite is converted into 
a purine analog (Table 4). When incorporated into nuclear 
DNA, this metabolite inhibits DNA synthesis and subsequent 
T- and B-cell proliferation [104]. AZA is typically used in 
conjunction with a CNI in maintenance therapy and is effec-
tive in preventing rejection when used in combination with 
CSA and steroids [38]. AZA has largely been replaced by 
newer agents, although it is still used by some clinicians 
when patients develop intolerable side effects from newer 
antiproliferative agents [94]. 
  Mycophenolate mofetil (MMF, Cellcept; Roche Labora-
tories, New Jersey, USA) has replaced AZA in current main-
tenance regimens (Table 4). Nearly 60% of patients started 
on cell cycle inhibitors are given MMF compared to AZA in 
21% [32]. Mycophenolate is a noncompetitive inhibitor of 
inosine monophosphate dehydrogenase, a key enzyme in de 
novo guanine nucleotide production. In proliferating lym-
phocytes, the only pathway for purine synthesis is de novo 
production, while in other cell lines, either salvage pathways 
or  de novo synthesis can be used. Thus, mycophenolate 
blocks lymphocyte proliferation without inhibiting other cell 
lines [104]. MMF is a pro-drug that is quickly metabolized 
to mycophenolic acid (MPA) in the patient. When compared 
to AZA, MMF has been shown to improve survival, reduce 
acute rejection rates, and decrease the incidence of coronary 
vasculopathy in adults [105-107]. In children, MMF allows 
Table 3.  Summary of Induction Agents [93, 94, 127] 
Class / Drug  Dosing  Side Effects 
Polyclonal Anti-thymocyte Globulin 
 Equine ATG  After subQ test dose, 7-15 mg/kg/d by slow IV infusion 
for 5-7 days 
Rash, fever, hypotension, serum sickness (with 
equine  
 Rabbit ATG  1.5 mg/kg/d for 3–7 days post-transplant by slow IV 
infusion 
preparation), anaphylaxis, cytokine release syn-
drome 
IL-2 Receptor Antibodies 
 Basiliximab   12 mg/m
2 up to 20 mg per dose in infused over 30 min 
on day 0 and day 4 post transplantation 
Risk of hypersensitivity, anaphylaxis 
 Daclizumab  1 mg/kg IV perioperatively and then every 2 weeks, for a 
total of five doses 
Risk of hypersensitivity, anaphylaxis 
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CNI dosing to be decreased which improves renal function 
without increasing rejection risk [108]. Because MPA levels 
have been correlated with rejection risk, MMF dosing should 
be concentration-driven rather than dose-driven since there is 
not a linear relationship between MPA trough level and 
MMF dose in children and young adults. First year MPA 
troughs <2.5 g/mL have been associated with increased 
rejection [109]. Recently introduced is an enteric-coated 
formulation of mycophenolic acid (Myfortic; Novartis 
Pharmaceuticals Corporation, New Jersey, USA). This for-
mulation appears equally efficacious with less gastrointesti-
nal toxicity compared to MMF in adults, although no similar 
comparative pediatric data is yet available [110].  
mTOR Inhibitors 
  Increasingly, sirolimus (RAPA, Rapamycin, Rapamune, 
Wyeth) is being used in pediatric transplantation (Table 4). 
RAPA inhibits the enzyme kinase mammalian target of ra-
pamycin (mTOR). mTOR phosphorylates cell-cycle regula-
tory proteins involved in the T-cell proliferation, disrupts 
growth and differentiation of B- and T-cell lymphocytes 
[104] and inhibits vascular smooth muscle proliferation [94]. 
Sirolimus is nephrotoxic, although much less so than CNIs 
[94]. In adults, sirolimus has been shown to decrease CNI-
induced renal insufficiency [111] and attenuate the develop-
ment of coronary vasculopathy [112, 113]. However, a re-
cent adult cohort study of CNI-free, primary mTOR inhibitor 
immune suppression in the immediate post-operative period 
demonstrated CNI-free regimens had increased early acute 
rejection, increased bacterial and fungal infections, and in-
creased pleural effusions when compared to CNI or 
CNI+mTOR regimens [114]. In the pediatric literature, small 
studies have shown sirolimus to be effective in allowing 
lower doses of CNI which reduces CNI side effects, includ-
ing renal toxicity, and as an adjunct treatment for rejection 
[115, 116]. Pediatric safety and efficacy for sirolimus re-
mains poorly established, although a small retrospective 
study demonstrated no increase in hyperlipidemia, rejection, 
or mortality after converting to a lower CNI dose regimen 
with adjunctive sirolimus [117]. Everolimus (Certican, No-
vartis) is an alternative mTOR inhibitor which has a similar 
side effect profile to sirolimus and has gained wide accep-
tance with adult transplant physicians, but thus far has lim-
ited application in pediatrics. 
Corticosteroids 
  Corticosteroids (steroids) have roles in induction, main-
tenance therapy, and the treatment of rejection [38]. Steroids 
inhibit the transcription factors activator protein-1 and nu-
clear factor kappa-B, which both have important roles in the 
production of cytokines including IL-1 and IL-2, GM-CSF, 
TNF-alpha, growth factors, gamma interferon, CD40 ligand, 
and others [94, 104]. These actions limit the number, func-
tion, and distribution of white blood cells and provide broad, 
Table 4.  Common Maintenance Immunosuppressive Agents [94, 104, 127, 128] 
Class / Drug  Dosing  Side Effects 
Calcineurin Inhibitors 
 Cyclosporine   Based on goal trough levels; usual require-
ment 4-15 mg/kg/day divided twice daily 
Nephrotoxicity, hypertension, hirsutism, gingival hypertrophy, hy-
perlipidemia, hyperkalemia, hypomagnesemia, seizures, encephalo-
pathy 
 Tacrolimus  Based on goal trough levels; usual require-
ment 0.05- 0.3 mg/kg/day divided twice 
daily  
Nephrotoxicity, hypertension, diabetes mellitus, alopecia, hyperka-
lemia, hypomagnesemia, headaches, paresthesias, seizures, encepha-
lopathy 
Anti-proliferatives 
 Azathioprine  Based on white blood cell counts; usual 
requirement 1 to 3 mg/kg/day  
Leukopenia, anemia, megaloblastic thrombocytopenia, pancreatitis, 
hepatitis, nausea, vomiting, diarrhea, anorexia, neoplasia 
 Mycophenolate Mofetil  25–50 mg/kg/day or 1,200 mg/m
2/day di-
vided twice daily; may target MPA trough 
levels 1.5-2 
Nausea, vomiting, diarrhea, abdominal pain, anorexia, anemia, leu-
kopenia 
m-TOR Inhibitors 
 Sirolimus  Based on goal trough levels; usual require-
ment 1–3 mg/m
2/day 
Hyperlipidemia, mucosal ulceration, anemia, thrombocytopenia, 
leukopenia, arthralgias, impaired wound healing, nephrotoxicity 
 Everolimus  Based on goal trough levels; usual require-
ment is 0.8mg/m/day 
Hyperlipidemia, hypertension stomatitis, anemia, thrombocytopenia, 
leukopenia, fatigue, impaired wound healing, nephrotoxicity 
Corticosteroids 
 Prednisone  Significant institutional variation; typical 
maintenance dose 0.05- 0.3 mg/kg/day 
Hypertension, hyperlipidemia, diabetes, growth retardation, osteopo-
rosis, increased infections, weight gain, adrenal suppression, cata-
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non-specific, immune suppression. Steroids are typically 
initiated during and immediately after surgery in high doses 
and subsequently tapered to lower maintenance dosing. Be-
cause of their side effect profile and long-term morbidities, 
many clinicians attempt to wean steroids off within several 
months of transplant depending on rejection history. None-
theless, according to the most recent international society 
report, nearly 40% of pediatric patients still receive predni-
sone 5 years post-transplant [32].  
  With the introduction of new immunsuppressive agents, 
“steroid avoidance”, or early, rapid steroid weaning is in-
creasingly targeted. A typical approach consists of 3-7 days 
of intravenous steroids in the peri-operative period followed 
by a rapid and complete taper off. Often these patients re-
ceive induction with Thymoglobulin followed by mainte-
nance immunosuppression with tacrolimus or cyclosporine 
in conjunction with an anti-proliferative agent, commonly 
mycophenolate mofetil. Using this approach in appropriately 
selected patients, multiple studies have demonstrated that 
steroid-free therapy provides survival and rejection rates 
similar to patients who continue to receive maintenance cor-
ticosteroid therapy [82, 118, 119]. Unfortunately, not all pa-
tients tolerate steroid avoidance and some require steroid re-
initiation secondary to late (>1 month post-transplant) or 
recurrent rejection [82]. For patients in whom avoidance was 
not tolerated or attempted, steroid withdrawal has been con-
sistently and successfully implemented over the last decade 
as a strategy to decrease the adverse late-effects of steroids. 
Patients who are maintained on longer-term (> 5 years) ster-
oids may be unable to taper off at all and seem to be at in-
creased risk for late rejection when tapered off particularly in 
older recipients who may be more steroid dependent [120].  
OUTCOME 
  Overall peri-operative and short-term survival after pedi-
atric transplant is good; >80% of patients survive to 1 year 
[32]. However, multiple studies have identified risk factors 
for mortality following pediatric heart transplant. Tjang and 
colleagues reported a single center series of 116 patients 
post-transplant and found that recipient age <1 year, recipi-
ent body height and body surface area, pre-transplant con-
genital heart disease, male donor, donor body height and 
surface area, and cardiopulmonary bypass time >210 minutes 
were associated with increased 30-day mortality. Multivari-
ate analysis determined that male donor and prolonged by-
pass time were independent risk factors for 30-day mortality 
[121].  
  A recent study by Davies re-examined high-risk criteria 
for pediatric transplant which have traditionally included 
pulmonary vascular resistance (PVR) >6 Uxm
2, renal failure, 
presence of hepatitis C antibody, donor/recipient weight ratio 
>0.7, PRA >40%, retransplantation, and age <1 year. To 
better assess if and to what extend these risk factors influ-
enced early survival, these investigators reviewed 3502 
transplant patients aged <21 years identified through the 
United Network for Organ Sharing (UNOS) database. They 
determined that mortality at 30 days and 1 year was indeed 
higher in patients with high-risk criteria. However, perhaps 
related to improvements in peri-operative management, in-
creased PVR, retransplantation, and high PRA did not inde-
pendently predict increased mortality. Of the traditional 
high-risk criteria, only renal failure was a risk factor for early 
mortality, but, factors including pre-operative ECMO, earlier 
era of transplant and pre-transplant congenital heart disease 
each added incremental risk [122].  
  Multiple studies have cited congenital heart disease 
(CHD) as an early mortality risk [19, 33, 121, 123]. How-
ever, the spectrum of CHD is broad. To better understand the 
factors that contribute to poor outcome in CHD patients, 
Lamour et al studied 488 patients transplanted with variable 
types of CHD including single ventricle lesions, d- and l-
transposition of the great arteries, right ventricular outflow 
tract obstruction, atrial and ventricular septation defects and 
others; 93% of the patients had at least 1 cardiac surgery 
prior to transplant. Overall, patients with CHD had signifi-
cantly lower survival at 3 months post-transplant than did 
cardiomyopathy patients. Risk factors for death were older 
recipient and donor ages and prolonged ischemic time. Fon-
tan palliated-patients had significantly increased risk of 
death compared to other CHD after transplant [123]. Al-
though the reasons for this decreased survival are multifacto-
rial, multiple previous intra-thoracic surgeries and elevated 
pulmonary vascular resistance due to nature of Fontan-
physiology are likely two of the main causes [123, 124]. In-
terestingly, the conditional risk of death for CHD patients 
who were alive at 3 months post-transplant was not different 
from pediatric patients with cardiomypathy suggesting that 
additional unidentified perioperative factors in the CHD 
group contribute to death [123]. Several smaller studies cor-
roborate similar survival between CHD and non-CHD pedi-
atric patients [125, 126]. In addition to an increased risk of 
allosensitization and elevated PVR that may have been un-
derestimated by pre-operative assessment, complex anatomy 
often requires challenging vascular reconstructions and com-
plicates surgical graft anastamoses. Furthermore, since many 
of these patients have had previous sternotomies, re-
operation is technically more difficult and the risks of bleed-
ing are significantly increased. A thorough understanding of 
the peri-operative factors that may affect short-term outcome 
in this group is therefore essential to ensure the best short 
and intermediate term survival.  
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